Search
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalIt was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States. … Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ).
Ketamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedIt was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332] … Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.
Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsProducts: Ketamin G.L. 10 mg/ml - Injektions-/Infusionslösung in Ampullen, Ketamin G.L. 50 mg/ml - Injektions-/Infusionslösung in AmpullenBelatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalFDA approved on June 15, 2011. … It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.
Pegzilarginase
go.drugbank.com/drugs/DB14780ApprovedFDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).
Testosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalTestosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. … It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
Astemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnAstemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]
Iobitridol
go.drugbank.com/drugs/DB12407ApprovedWithdrawnIobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.
Categories: Compounds used in a research, industrial, or household settingNorepinephrine
go.drugbank.com/drugs/DB00368ApprovedInvestigationalIt is also found in plants and is used pharmacologically as a sympathomimetic. … Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus.
Products: N-EPI, Norepinephrine Bitartrate In Sodium Chloride